Cancer – ADVL1712: Feasibility Trial of MLN4924 Given in Combination with Azacitidine, Fludarabine and Cytarabine, in Children, Adolescents and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia or Relapsed Myelodysplastic Syndrome
Condition or Therapy:
Cancer and Blood Disorders
Study Number: ADVL1712
What is the goal of this study?
This phase I trial studies the side effects of how well pevonedistat, azacitidine, fludarabine phosphate and cytarabine work in treating patients with acute myeloid leukemia that has come back or has not responded to treatment or high-risk myelodysplastic syndrome that has come back.
Who can join the study?
This study might be a good fit for children and young adults who:
- Are 1 month to 21 years old
- Have had recurrent or refractory AML
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or send us an email.